NCT03686501View on ClinicalTrials.gov

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

March 28, 2019

Study Completion Date

March 28, 2019

Conditions
Healthy Male Volunteers
Interventions
DRUG

PF-06412562

Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

Invicro
All Listed Sponsors
lead

Invicro

OTHER

NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 | Biotech Hunter | Biotech Hunter